# US 2026/0125691 A1 · Tcd34 And Other Markers For Identification And Sorting Of Cells And For Use As In Vivo Tracking Assistant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125691 A1
- Document ID: US20260125691A1
- Status: Published application
- Kind: A1
- Application number: 18/685,881
- Filed: 2022-08-26
- Published: 2026-05-07
- Earliest claimed: 2021-08-30
- Assignees: CarryGenes Bioengineering, LLC
- Applicants: CarryGenes Bioengineering, LLC
- Inventors: Edward L PERKINS; Amy L GREENE; Dominique BROCCOLI; Kara Pascarelli MANNE; Ola WINQVIST; John ANDERSSON; Marton KESZEI; Katarina LYBERG; Maria EKOFF; Julia REMNESTÅL
- Web page: https://patentgrep.com/patent/US20260125691A1

## CPC

- A61K 40/4234: {Interleukins [IL]}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/35: Cytokines
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4219: {Receptors for chemokines}
- A61K 40/4266: {Carcinoembryonic antigen [CEA]}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/5418: {IL-7}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/7158: {for chemokines}
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/32: against translation products of oncogenes
- C12N 5/0636: {T lymphocytes}
- C12N 5/0662: {Stem cells}
- C12N 9/6472: {Cysteine endopeptidases (3.4.22)}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/65: using markers (enzymes used as markers C12N15/52)
- C12N 15/85: for animal cells
- C12Y 304/22062: Caspase-9 (3.4.22.62)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55533: {IL-2}
- A61K 2039/55538: {IL-12}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C12N 2501/21: Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/392: Sexual steroids
- C12N 2501/50: Cell markers; Cell surface determinants
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2510/00: Genetically modified cells
- C12N 2510/02: Cells for production
- C12N 2800/20: Pseudochromosomes, minichrosomosomes
- C12N 2800/204: of bacterial origin, e.g. BAC
- C12N 2800/208: of mammalian origin, e.g. minichromosome
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Use of one or more markers to identify and sort cells that have been engineered to comprise a synthetic chromosome encoding the marker(s), with said cells expressing said marker(s) encoded on the synthetic chromosome. The marker is typically but not limited to a cluster of differentiation (CD), wherein the CD has been truncated or otherwise modified so that the biological function of the CD is lost or remarkably reduced. The modified CD is typically used to sort cells to obtain a desired population of cells containing the synthetic chromosome, or i) to ensure that a cell population administered to a subject, e.g., suffering from cancer, reaches the target tissue, ii) to ensure that a cell population administered to a subject, e.g., suffering from cancer, stays at the desired site within the body of the subject during a treatment regimen, iii) to make it possible to turn on a kill switch comprised in the synthetic chromosomes of the cells of the cell population if the cell population is present at undesired sites in the body, or iv) to use as a diagnostic tool.

## Claims

### Claim 1

A synthetic chromosome comprising a nucleic acid sequence encoding a surface marker.

### Claim 2 (depends on 1)

A synthetic chromosome according to claim 1, wherein the surface marker is a cluster of differentiation.

### Claim 3 (depends on 2)

A synthetic chromosome according to claim 2, wherein the cluster of differentiation is truncated.

### Claim 4

A synthetic chromosome according to any one of the preceding claims, wherein the surface marker, when expressed by a cell
i) contains the antigen epitope, and
ii) does not induce signaling in the cell, and/or
iii) does not bind to the putative ligand.

### Claim 5

A synthetic chromosome according to any one of the preceding claims, wherein the surface marker is select from CD34, trCD34, CD20, trCD20, CD19, trCD19, CD14, and trCD14.

### Claim 6

A synthetic chromosome according to any one of the preceding claims, wherein the surface marker is trCD34.

### Claim 7

A synthetic chromosome according to any one of the preceding claims comprising two or more nucleic acid sequences encoding two or more surface markers, wherein the surface markers may be the same or different.

### Claim 8

A synthetic chromosome according to any one of the preceding claims comprising one or more inducible promotors independently controlling expression of one or more surface markers.

### Claim 9

A synthetic chromosome according to any one of the preceding claims comprising one or more insulators.

### Claim 9

A synthetic chromosome according to any one of the preceding claims for use in identifying and/or sorting cells expressing a surface marker.

### Claim 10

A synthetic chromosome according to any one of the preceding claims for use in in vivo tracking of cells expressing a surface marker.

### Claim 11

A cell comprising a synthetic chromosome as defined in any one of the preceding claims.

### Claim 12

A cell according to any of the preceding claims for medical use, veterinary use, or diagnostic use.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A composition comprising a synthetic chromosome as defined in any one of claim 1-10 and an additive.

### Claim 14 (depends on 11, 12)

A composition comprising a cell as defined in claim 11 or 12 and an additive.
